Daniel Engelman to Randomized Controlled Trials as Topic
This is a "connection" page, showing publications Daniel Engelman has written about Randomized Controlled Trials as Topic.
Connection Strength
0.398
-
Ostermann M, Corteville DC, Doi K, Koyner JL, Lamy A, Li G, Solinsky CM, Winterberg PD, Smith WT, Mehta RL, Murray PT, Shaw AD, Zarbock A, Engelman DT. A phase 3 study of ravulizumab to protect patients with chronic kidney disease from cardiac surgery-associated acute kidney injury and major adverse kidney events (ARTEMIS). Trials. 2025 May 30; 26(1):181.
Score: 0.186
-
Spadaccio C, Salsano A, Pisani A, Nenna A, Nappi F, Osho A, D'Alessandro D, Sundt TM, Crestanello J, Engelman D, Rose D. Enhanced recovery protocols after surgery: A systematic review and meta-analysis of randomized trials in cardiac surgery. World J Surg. 2024 Apr; 48(4):779-790.
Score: 0.171
-
Mazer CD, Siadati-Fini N, Boehm J, Wirth F, Myjavec A, Brown CD, Koyner JL, Boening A, Engelman DT, Larsson TE, Renfurm R, de Varennes B, Noiseux N, Thielmann M, Lamy A, Laflamme M, von Groote T, Ronco C, Zarbock A. Study protocol of a phase 2, randomised, placebo-controlled, double-blind, adaptive, parallel group clinical study to evaluate the efficacy and safety of recombinant alpha-1-microglobulin in subjects at high risk for acute kidney injury following open-chest cardiac surgery (AKITA trial). BMJ Open. 2023 04 06; 13(4):e068363.
Score: 0.040